Australia follows suit in gene patent battle
In March, we blogged on the decision of a US district judge which held that patents directed to the detection of inheritable breast cancer were invalid (click here to read our earlier post). Hot on the heels of the US decision comes an attack on the validity of Myriad Genetics’ Australian patent for the gene mutation BRCA1 (commonly known as the breast cancer gene).